Clinical Trial Update: Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial of bimiralisib in head and neck squamous cell carcinoma with NOTCH1 loss-of-function mutations was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• bimiralisib (bimiralisib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: HNSCC | Phase 2 | Status: TERMINATED | Results posted: 2022-01-20